Meet cardiologist Professor Renato Lopes and learn more about the ground breaking AUGUSTUS trial in patients with atrial fibrillation with ACS and/or PCI in these video interviews.
Professor Lopes introduces himself.
We have come a long way in the past 10 years with the development of new drugs for stroke prevention with lower bleeding risk. Find out more.
Learn about the trial which answered two important questions to help in clinical decision making.
Find out why less is definitely more in terms of bleeding with a regime of apixaban and a P2Y12 inhibitor.
Find out more about the most recent trial testing a DOAC.
Find out about why AUGUSTUS is the heavyweight of the meta-analysis.
Find out how the recent meta-analysis adds weight to the ‘less is more’ argument when treating patients with atrial fibrillation with ACS and/or PCI.
Learn why double therapy is a safe strategy for most patients but longer aspirin treatment might still be suitable for some patients.
Professor Lopes describes how the AUGUSTUS study has answered this question for the majority of patients.
Find out why we are currently in a new era of anticoagulation.
Find out what the trade-off is when using a DOAC.
Back to Expert Opinion
Alternatively login via
Back to epgonline.org